Indoco Remedies Ltd. has announced that its Clinical Research Organisation, Anacipher, located at Hyderabad had undergone a walk-in surveillance inspection by the United States Food and Drug Administration (division of New Drug Bioequivalence Evaluation) from 5th August to 9th August, 2019. The inspection successfully concluded without any observations and no form 483 is issued.

"This is the fourth successive USFDA inspection with ZERO 483 for our CRO - AnaCipher. We are committed to strict adherence to regulatory guidance and maintaining highest standards in delivering quality services to our clients.", stated Ms. Aditi Kare Panandikar, Managing Director, Indoco Remedies Limited.

The CRO - AnaCipher conducts Bio-Equivalence and Bio-Availability (BA/BE) studies at its facility spread over an area of 30,000 sq. ft. with 98 beds. CRO also has expertise in Bio-Analytical work for new chemical entities (Phase I-III studies).

Shares of INDOCO REMEDIES LTD. was last trading in BSE at Rs.152.6 as compared to the previous close of Rs. 152.75. The total number of shares traded during the day was 7924 in over 588 trades.

The stock hit an intraday high of Rs. 163.65 and intraday low of 151.15. The net turnover during the day was Rs. 1239992.

Source: Equity Bulls